145 results about "Subcutaneous injection" patented technology

The invention discloses a preparation method of a self-crosslinking hyaluronic acid microsphere without an exogenous crosslinking agent, which comprises the following steps: activating carboxyl on hyaluronic acid only by using an activator with good biocompatibility, carrying out esterification reaction on the activated carboxyl and hydroxyl on the hyaluronic acid, and curing and crosslinking water-in-oil emulsion at room temperature by continuously stirring to obtain the self-crosslinking hyaluronic acid microsphere without the exogenous crosslinking agent. The self-crosslinking hyaluronic acid microspheres are formed. As an exogenous cross-linking agent is not introduced, hyaluronic acid forms an ester bond through self-crosslinking after being activated instead of forming an amido bond with the exogenous cross-linking agent, and the formation of the ester bond can effectively improve the storage modulus of the hyaluronic acid microspheres. Compared with a commercially available sieved gel product, the self-crosslinked hyaluronic acid microsphere disclosed by the invention has the advantages that the crosslinking degree is higher, the immunogenicity risk of free HA is reduced, the self-crosslinked hyaluronic acid microsphere is suitable for deep or subcutaneous injection of dermis, and a more uniform three-dimensional support is provided.

The invention disclosed concerns a fixed dose combination (FDC) of pertuzumab, trastuzumab, and, optionally, recombinant human hyaluronidase (rHuPH20), which is administered subcutaneously to patients. The final efficacy and safety data for the FeDeriCa clinical trial, United States Prescribing Information (USPI) (including home-use) methods, and primary analysis of the PHranceSCa clinical trial are disclosed and claimed.

To provide a highly concentrated liquid antibody formulation that is storage stable and suitable for subcutaneous administration.SOLUTION: The present disclosure inter alia provides a liquid pharmaceutical formulation comprising a) 150 mg / ml of an anti-IL-23p19 antibody, the antibody comprising a specific light chain amino acid sequence and a specific heavy chain amino acid sequence; b) a polyol; and c) a surfactant.SELECTED DRAWING: None

Most therapeutic treatments require dose adjustment after initial administration. Dosage adjustment is crucial to ensuring optimal safety and efficacy characteristics of the treatment. Gene therapy is inherently limited by the inability to adjust the dose after initial administration. This invention describes a genetic element capable of dose adjustment after the initial administration of gene therapy. The realization of dose adjustment allows for the replacement of multiple subcutaneous protein injection regimens with single-injection gene therapy, thereby improving pharmacokinetics, safety / efficacy characteristics, medication adherence, and reducing healthcare costs.

The present invention relates to aqueous compositions comprising dantrolene and optionally also at least one additional active principle, such as botulinum neurotoxin, and their use for various therapeutic and / or aesthetic / cosmetic purposes. The compositions can be administered in any suitable way but are advantageous in that they are particularly well adapted to intramuscular injection, subcutaneous injection and / or intradermal injection.

A pharmaceutical combination for subcutaneous administration and use thereof are provided. The pharmaceutical combination as described herein for subcutaneous administration includes a hyaluronidase and an antibody-drug conjugate. The antibody-drug conjugate includes a fragment of a bioactive molecule, and the bioactive molecule has moderate toxicity. The pharmaceutical combination can achieve a larger volume and a larger dose of administration, and the side reaction is not enhanced.

The invention relates to compositions and methods for treating cancer in a patient comprising subcutaneously administering a PD-1 antagonist, e.g., an anti-PD-1 antibody (e.g. pembrolizumab), or antigen binding fragment thereof, with or without hyaluronidase every six weeks, in specific amounts to the patient. In specific embodiments, the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 600 mg to about 1000 mg. In specific embodiments, the administration occurs about every three weeks, and the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 300 mg to about 500 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits formulated for subcutaneous administration comprising a particular dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.

The present disclosure provides methods for treating thyroid eye disease, comprising subcutaneously administering a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment to a patient in need of treatment. Also provided herein are pharmacologically active agents, compositions, methods, and / or administration schedules for the treatment of thyroid eye disease.

This invention belongs to the field of vertebrate technology, specifically relating to a method for constructing a complex inflammatory animal model in middle-aged and elderly individuals and its related applications. The method includes: selecting adult animals for adaptive feeding, daily subcutaneous injection of D-galactose to establish a susceptibility to aging and oxidative stress, and administering sodium dextran sulfate (DSS) solution within a specific time window to induce intestinal inflammation, forming a complex inflammatory state through gut-hepatic axis interactions. The constructed animal model simultaneously exhibits intestinal inflammatory damage, abnormal hepatic oxidative stress, and aging-related characteristics, realistically simulating the pathological process of gut-hepatic axis dysfunction in middle-aged and elderly individuals. This model is suitable for screening and evaluating drugs, medical nutrition products, and functional foods that improve gut-hepatic axis dysfunction, providing a reliable technical platform for research on related disease mechanisms and the development of interventional substances.

The present invention relates to nanoparticles comprising sirolimus and albumin, a pharmaceutical composition comprising the same for subcutaneous administration, and a method for preparing the same. In the case of using the preparation method of the present invention, nanoparticles comprising sirolimus and albumin having excellent stability of particle size distribution can be prepared, the prepared nanoparticles can be prepared as a pharmaceutical composition suitable for subcutaneous injection, and the increase in administration dose and the convenience of administration can be improved.

The invention relates to a device (100), particularly a cosmetic one, for the subcutaneous injection of gas, in particular carbon dioxide (CO2), comprising a gas reservoir (10) in fluidic communication with a hollow microneedle (4) having an internal channel of mean internal transverse dimension (IDmoy), the hollow injection microneedle (4) having a length (L) less than or equal to 250 mm and greater than or equal to 70 mm. [Fig. 1]

The invention relates to the technical field of medical instruments, in particular to an application type ultrathin subcutaneous injection device which comprises a storage layer, a storage groove used for storing liquid medicine is formed in the top of the storage layer, and a filling assembly used for supplementing the liquid medicine is arranged at the top of the storage layer; a driving layer is fixedly connected to the bottom of the storage layer, a liquid inlet cavity and a liquid outlet cavity are formed in the top of the driving layer, a liquid outlet is formed in the storage groove and communicates with the liquid inlet cavity, and the communicating position of the liquid outlet and the liquid inlet cavity communicates with a first one-way valve for feeding liquid into the liquid inlet cavity; the liquid inlet cavity is communicated with the liquid discharging cavity, and a second one-way valve for discharging liquid from the liquid inlet cavity is communicated with the communicating part of the liquid inlet cavity and the liquid discharging cavity; the bottom of the driving layer is fixedly connected with an injection layer; an injection cavity is formed in the top of the injection layer and is communicated with the liquid discharge cavity; through the design of the storage layer, the driving layer and the injection layer, the size of the device can be effectively reduced, the body burden of a patient is effectively relieved, and the convenience of the device and the comfort of the patient are improved.

This utility model discloses a portable syringe plunger auxiliary device, comprising: a base and a power supply module. A syringe holder and an electric plunger are mounted on the base; the syringe holder is configured to engage an injection syringe; the electric plunger is positioned such that its output shaft extends toward the syringe holder, and the electric plunger pushes the piston handle of the injection syringe engaged in the syringe holder toward the needle tip of the injection syringe; the power supply module is installed within the base and electrically connected to the electric plunger through a first power supply circuit, and the power supply module supplies power to the electric plunger. This utility model helps nursing personnel achieve a stable and uniform injection operation over a long period during subcutaneous injections.

1. The name of the design product: insulin injection simulation artificial skin. 2. The use of the design product: the product is mainly used to demonstrate injection site selection and injection process in subcutaneous injection education process. 3. The design points of the design product: the combination of shape, pattern and color. 4. The picture or photo that best indicates the design points: perspective view. 5. The design for which protection is sought contains color. 6. The back of the design product is a part that is not easy to see or cannot be seen during use, and the rear view is omitted.

The invention discloses a method for preparing silk fibroin and hyaluronic acid composite gel, which comprises the following steps of: uniformly mixing hyaluronate with a first solvent to prepare hyaluronic acid gel, mixing the hyaluronic acid gel with a silk fibroin solution, shearing at a high speed, homogenizing and emulsifying, standing, shearing at a high speed, homogenizing and emulsifying, sealing and sterilizing to obtain the silk fibroin and hyaluronic acid composite gel. According to the method disclosed by the invention, reagents such as a cross-linking agent, an initiator and enzyme do not need to be additionally added; the silk fibroin solution and the hyaluronic acid gel can form uniform and mutually-crosslinked double networks in the homogeneous gel forming process, the phase separation risk is low, and the silk fibroin can generate an emulsion reaction through high-speed homogenization, so that the color of the composite gel is whiter; the preparation method disclosed by the invention is simple, rapid in emulsification and gel forming, short in production cycle, low in endotoxin of the product, high in biocompatibility, slow in degradation, small in inflammatory response and high in injection filling safety, and the composite gel can play a role in moisturizing and moisturizing after subcutaneous injection and has the whitening effects of improving skin elasticity and glossiness, fading fine wrinkles and the like.

The invention discloses near-infrared thermal molecules, nano particles, injectable near-infrared thermal hydrogel and application of the injectable near-infrared thermal hydrogel in preparation of anti-obesity drugs. The structural formula of the near-infrared photothermal molecule is shown in the specification. According to the invention, molecular structure design is carried out to obtain near-infrared thermal molecules with strong near-infrared absorption, bright near-infrared two-region fluorescence emission and high photo-thermal stability; near-infrared photothermal molecules are packaged into spherical nanoparticles by using an amphiphilic polymer through a nanoprecipitation method, the spherical nanoparticles are further mixed with a temperature-sensitive matrix material to prepare the near-infrared photothermal hydrogel capable of being subcutaneously injected, after near-infrared irradiation, adipocyte apoptosis can be remarkably induced, meanwhile, white fat is promoted to be converted into beige fat, and the effect of preparing the near-infrared photothermal hydrogel is achieved. The efficient anti-obesity effect is achieved; and hydrogel degradation, medicament distribution and treatment processes can be tracked in real time through near-infrared two-region fluorescence imaging, so that the controllability and accuracy of treatment are improved. The whole system shows good biocompatibility, and has outstanding application potential in the anti-obesity field.

Provided herein are ketamine formulations for subcutaneous injection, in particular subcutaneous formulations of ketamine useful for the treatment of various diseases and disorders. The subcutaneous ketamine preparation provided by the invention reduces stimulation and pain of an injection site.

A stable pharmaceutical formulation according to the present invention comprises: (A) Ixekizumab; and (B) a histidine buffer. A stable pharmaceutical formulation according to the present invention comprises an antibody, has excellent long-term storage stability on the basis of having excellent stability especially under accelerated conditions and severe conditions, and can be administered intravenously or subcutaneously.

The present invention relates to a composition comprising a photosensitizer use in prevention or treatment of dermatological disease in a patient, wherein the composition is used in the following order of steps: (a) topical application or subcutaneous injection of said composition to an area of the skin of said patient, (b) exposure of at least said area of the skin to light with a wavelength spectrum similar or identical to sun light for a duration of 30 min to 5 hours, and (c) exposure of at least said area of the skin to light of a wavelength spectrum comprising only one maximum in the absorbance spectrum of said photosensitizer as well as to methods of treating dermatological disease using the outlined steps and kits of parts comprising such compositions and light sources suitable to apply the respectively indicated light.

The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.

The invention belongs to the technical field of biology, and relates to a construction method of a renal tubular interstitial nephritis-uveitis syndrome mouse model. Comprising the following steps: anesthetizing a mouse; carrying out subcutaneous injection on photoreceptor intercellular vitamin A binding proteins and a complete Freund's adjuvant on the front neck, the thighs on the two sides and the back of the anesthetized mouse, and carrying out active immunization; and performing intraperitoneal injection on the actively immunized mouse by adopting pertussis toxin, and performing final immunization. According to the invention, the renal tubular interstitial nephritis-uveitis syndrome mouse model is successfully constructed, so that a foundation is laid for subsequent pathological mechanism research of the disease, and a support can be provided for further development of medicine research for treating the disease.

The present disclosure provides a storage-stable solid composition comprising a biopharmaceutical agent and a polyacrylamide-based copolymer. The present inventors have demonstrated that particular polyacrylamide-based copolymers can be used as stabilizing excipients in lyophilized formulations of biopharmaceutical agents. Methods of reconstituting and using the compositions are also provided, including methods of administering the reconstituted compositions to a human subject in need thereof by injection, e.g., subcutaneous injection.

The present disclosure relates to a pharmaceutical formulation suitable for sublingual administration for use in the treatment of obesity, type II diabetes, or related diseases. The pharmaceutical formula comprises 5 to 10 milligrams of glucagon-like peptide-1 receptor agonist peptide (GLP-1 RA-P) which is dissolved in 1.5 to 2.0 milliliters of a buffer solution, and the pH (Potential of Hydrogen) value of the pharmaceutical formula is 5.5 to 7.5. The disclosure also discloses a method for treating obesity, type II diabetes, or related diseases. The method comprises administering the pharmaceutical formulation of the present disclosure to a subject in a sublingual administration, and allowing the pharmaceutical formulation to be continuously located sublingually of the subject for 5-10 minutes, where the pharmaceutical formulation has a bioavailability for GLP-1 RA-P of 2-10% compared to the administration to the subject through subcutaneous injection.

A method for subcutaneously administering an isolated anti-CD38 antibody at low doses is disclosed. This method provides effective treatment for autoimmune diseases, including hematological disorders, and cancer. A unit dosage form of the anti-CD38 antibody is also disclosed. [Selected Figure] Figure 1

This invention provides an improved formulation and administration method of an FcRn inhibitor for use in the treatment of autoimmune diseases. [Solution] An aqueous formulation containing approximately 100-300 mg / mL of an FcRn antagonist, 20-60 mM histidine / histidine HCl, 0-70 mM sucrose, 0-150 mM NaCl, 0-250 mM arginine HCl, 0%-0.05% (w / v) polysorbate 20 or polysorbate 80, and 0-15 mM L-methionine. The aqueous formulation has a pH of 6.0-6.5, and the FcRn antagonist consists of a variant Fc region, which consists of two Fc domains that form a homodimer.

Provided herein are subcutaneous formulations of ketamine that are useful for treating a variety of disease and disorders. The subcutaneous ketamine formulations provided herein reduce injection site irritation and pain.

The present disclosure provides, among other things, methods and compositions for the oral administration of polypeptides. Many polypeptides are typically administered in liquid solutions by intravenous or subcutaneous injection. The present disclosure provides methods and compositions that include a polypeptide formulation, e.g., truffle, tablet, globule, candy, capsule formulation suitable for oral administration, where the formulation includes an amorphous polypeptide composition or a crystallized polypeptide composition and a pharmaceutically acceptable carrier.

The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of an isomer or analog of monoterpene or sesquiterpene (or its derivative), such as an isoperillyl alcohol. The present invention also provides for a method of treating a disease comprising the step of administering to a patient a therapeutically effective amount of a derivative of an isomer or analog of monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The derivative may be an isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

To provide formulations of anti-CD38 antibodies suitable for subcutaneous administration to a subject in need thereof.SOLUTION: Formulations include a high concentration of antibody, a viscosity lowering agent, a stabilizing agent, a buffering agent, and a surfactant. In certain embodiments, the viscosity of the solution is at most 25 mPa s, and the pH of the solution is 5.9-7.0. In certain embodiments, the anti-CD38 antibody is isatuximab. The formulations are useful in treating CD38+ hematological malignancies, including multiple myeloma, as well as autoimmune and inflammatory diseases, in humans.SELECTED DRAWING: None

The utility model provides a subcutaneous injection device which comprises a needle cylinder seat, a push rod driving seat, a main machine and an angle seat and can be used for long-time subcutaneous injection, when the device is used, after the device is fixed on a thigh by means of the angle seat, automatic needle feeding and automatic pushing can be achieved by means of the angle seat, and only a corresponding motor needs to be started. According to the automatic subcutaneous injection device, subcutaneous injection can be automatically carried out according to time and speed, the two hands of nursing personnel can be liberated, clinical service can be more effectively achieved, the operation burden of medical personnel is relieved, the set angle and speed can be always kept in the needle inserting and medicine pushing process, the needle inserting and medicine pushing process can be accurately carried out according to setting of electric equipment, and the subcutaneous injection quality can be better ensured.